Sermorelin: Peptide Profile, CAS & Properties
CAS 86168-78-7 · 3357.93 g/mol
Sermorelin (CAS 86168-78-7) is a synthetic 29-amino-acid peptide corresponding to the active 1-29 fragment of human growth hormone-releasing hormone (GHRH), a GHRH analogue / GH secretagogue. It is not currently an approved FDA or EMA drug. This page provides reference information on Sermorelin.
- CAS Number
- 86168-78-7
- Molecular Formula
- C149H246N44O42S
- Molecular Weight
- 3357.93 g/mol
- Drug Class
- GHRH(1-29) analogue / GH secretagogue
What is Sermorelin?
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the biologically active 1-29 fragment of endogenous human growth hormone-releasing hormone (GHRH), terminated as a C-terminal amide. Mechanistically it acts as a GHRH analogue: it binds the growth hormone-releasing hormone receptor (GHRHR) on somatotroph cells of the anterior pituitary, mimicking native GHRH and stimulating the synthesis and pulsatile release of endogenous growth hormone.
As a chemical compound, sermorelin (CAS 86168-78-7, molecular formula C149H246N44O42S, ~3357.93 g/mol) is typically encountered as a lyophilised powder. A branded sermorelin product was approved by the US FDA in 1997 for growth hormone deficiency but was voluntarily withdrawn from the market in 2008 for commercial reasons; there is no marketed FDA- or EMA-approved sermorelin drug today.
How Sermorelin Is Produced & Characterised
Sermorelin is a 29-mer peptide whose length, multiple Arg/Lys basic residues and C-terminal amide create opportunities for deletion sequences, oxidation at the single methionine and incomplete amidation. Industry-standard production of peptides in this class uses Fmoc solid-phase peptide synthesis (SPPS) on an amide-forming resin, with controlled coupling and capping to suppress related-substance formation. The crude peptide is typically purified on preparative dynamic axial compression (DAC) reversed-phase HPLC columns, which resolve the target sequence from closely related impurities, and is then lyophilised to a stable powder.
Analytical characterisation of such peptides generally relies on UPLC/HPLC for purity, LC-MS for confirmation of the sequence and identification of minor structural variants, and complementary assays for water content, counter-ion (e.g. acetate) content, residual solvents, methionine-oxidation level and peptide content. These approaches are described here as general reference information about how the molecule is made and analysed.
Typical Quality Specifications & Impurity Profile
Reference-grade and research-grade sermorelin is commonly characterised to a defined specification. Purity is determined by UPLC/HPLC, with target purities frequently reported at ≥99.0% and individual impurities controlled below 0.10%, while sequence and minor structural variants are confirmed by LC-MS impurity profiling. Stability behaviour is typically assessed under ICH Q1A(R2) long-term and accelerated conditions.
Known degradation pathways for the molecule include oxidation at its single methionine residue, deletion sequences arising from incomplete coupling, and incomplete C-terminal amidation. Analytical methods used to characterise these attributes are generally validated to ICH Q2(R1). This information reflects typical analytical practice for the peptide and is provided for educational reference only.
Regulatory Status & Reference Context
Sermorelin is not currently an approved drug in major markets. A branded sermorelin product received US FDA approval in 1997 for growth hormone deficiency but was voluntarily withdrawn from the US market in 2008 for commercial reasons, and there is no marketed FDA- or EMA-approved sermorelin drug today.
Where sermorelin is referenced in research, characterisation documentation such as CTD Module 3 CMC sections, analytical validation data to ICH Q2(R1), impurity and structural characterisation data, and stability data are the types of records typically associated with development-stage peptides. The molecule is described here strictly as reference information, with no therapeutic or efficacy claims.
Sermorelin API — Specifications
| Compound | Sermorelin |
|---|---|
| CAS Number | 86168-78-7 |
| Molecular Formula | C149H246N44O42S |
| Molecular Weight | 3357.93 g/mol |
| Sequence | 29 amino acids, C-terminal amide (GHRH 1-29) |
| Drug Class | GHRH(1-29) analogue / GH secretagogue |
| Appearance | White to off-white lyophilised powder |
| Typical Purity (HPLC) | ≥ 99.0% reported (single impurity < 0.10%) |
| Synthesis Route | Fmoc SPPS + DAC prep-HPLC purification |
| Regulatory Status | No current FDA/EMA-approved drug (1997 approval withdrawn 2008) |
| Form | Lyophilised powder; typically stored at -20°C, protected from light & moisture |
Reference data only — WinHyCare neither supplies nor manufactures this compound; see our Semaglutide API for the product we supply. Regulatory status: Not currently approved by the FDA or EMA for therapeutic use. A branded sermorelin product was FDA-approved in 1997 but was voluntarily withdrawn from the US market in 2008 for commercial reasons; there is no marketed FDA-approved sermorelin drug today.
Sermorelin API — Frequently Asked Questions
What is Sermorelin?
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the biologically active 1-29 fragment of human growth hormone-releasing hormone (GHRH), with a C-terminal amide. It acts as a GHRH analogue and growth hormone secretagogue.
What is the CAS number and molecular weight of Sermorelin?
Sermorelin's CAS number is 86168-78-7, its molecular formula is C149H246N44O42S, and its molecular weight is approximately 3357.93 g/mol.
Is Sermorelin approved by the FDA or EMA?
Not currently. A branded sermorelin product received US FDA approval in 1997 but was voluntarily withdrawn from the US market in 2008 for commercial reasons, and there is no marketed FDA- or EMA-approved sermorelin drug today.
What class of peptide is Sermorelin?
It is a GHRH(1-29) analogue and growth hormone secretagogue. As a GHRH analogue it binds the growth hormone-releasing hormone receptor (GHRHR) on somatotroph cells of the anterior pituitary, mimicking native GHRH and stimulating the synthesis and release of endogenous growth hormone. This is a factual description, not a therapeutic claim.
What has Sermorelin been studied for?
Sermorelin has historically been associated with growth hormone deficiency; a branded product was FDA-approved for that indication in 1997 before being withdrawn in 2008. There is no current approved sermorelin drug. This page makes no therapeutic or efficacy claims about the molecule.
How is Sermorelin typically produced?
Peptides in this class are generally produced by Fmoc solid-phase peptide synthesis (SPPS) on an amide-forming resin, purified by preparative dynamic axial compression (DAC) reversed-phase HPLC, and lyophilised to a stable powder. This describes typical industry methods, not any specific supplier's activity.
Related Peptide APIs
Tesamorelin API
CAS 218949-48-5
Growth & MetabolismCJC-1295 API
CAS 863288-34-0
Growth & MetabolismAOD-9604 API
CAS 221231-10-3
GastrointestinalTeduglutide API
CAS 197922-42-2
Technical Reference Page
WinHyCare neither supplies nor manufactures Sermorelin; this page is provided as a technical reference. The peptide API we supply is Semaglutide.